GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » OncoMed Pharmaceuticals Inc (NAS:OMED) » Definitions » ROIC %

OncoMed Pharmaceuticals (OncoMed Pharmaceuticals) ROIC % : -114.29% (As of Dec. 2018)


View and export this data going back to 2013. Start your Free Trial

What is OncoMed Pharmaceuticals ROIC %?

ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. OncoMed Pharmaceuticals's annualized return on invested capital (ROIC %) for the quarter that ended in Dec. 2018 was -114.29%.

As of today (2024-04-26), OncoMed Pharmaceuticals's WACC % is 0.00%. OncoMed Pharmaceuticals's ROIC % is 0.00% (calculated using TTM income statement data). OncoMed Pharmaceuticals earns returns that do not match up to its cost of capital. It will destroy value as it grows.


OncoMed Pharmaceuticals ROIC % Historical Data

The historical data trend for OncoMed Pharmaceuticals's ROIC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

OncoMed Pharmaceuticals ROIC % Chart

OncoMed Pharmaceuticals Annual Data
Trend Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18
ROIC %
Get a 7-Day Free Trial Premium Member Only -124.43 -206.86 -236.06 -61.64 -16.14

OncoMed Pharmaceuticals Quarterly Data
Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18
ROIC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 65.42 -38.70 -56.51 101.61 -114.29

Competitive Comparison of OncoMed Pharmaceuticals's ROIC %

For the Biotechnology subindustry, OncoMed Pharmaceuticals's ROIC %, along with its competitors' market caps and ROIC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


OncoMed Pharmaceuticals's ROIC % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, OncoMed Pharmaceuticals's ROIC % distribution charts can be found below:

* The bar in red indicates where OncoMed Pharmaceuticals's ROIC % falls into.



OncoMed Pharmaceuticals ROIC % Calculation

OncoMed Pharmaceuticals's annualized Return on Invested Capital (ROIC %) for the fiscal year that ended in Dec. 2018 is calculated as:

ROIC % (A: Dec. 2018 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (A: Dec. 2017 ) + Invested Capital (A: Dec. 2018 ))/ count )
=-8.194 * ( 1 - 4.5% )/( (90.043 + 6.913)/ 2 )
=-7.82527/48.478
=-16.14 %

where

OncoMed Pharmaceuticals's annualized Return on Invested Capital (ROIC %) for the quarter that ended in Dec. 2018 is calculated as:

ROIC % (Q: Dec. 2018 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Sep. 2018 ) + Invested Capital (Q: Dec. 2018 ))/ count )
=-12.66 * ( 1 - -0.02% )/( (15.246 + 6.913)/ 2 )
=-12.662532/11.0795
=-114.29 %

where

Note: The Operating Income data used here is four times the quarterly (Dec. 2018) data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


OncoMed Pharmaceuticals  (NAS:OMED) ROIC % Explanation

ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROIC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, OncoMed Pharmaceuticals's WACC % is 0.00%. OncoMed Pharmaceuticals's ROIC % is 0.00% (calculated using TTM income statement data).


Be Aware

Like ROE % and ROA %, ROIC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.


OncoMed Pharmaceuticals ROIC % Related Terms

Thank you for viewing the detailed overview of OncoMed Pharmaceuticals's ROIC % provided by GuruFocus.com. Please click on the following links to see related term pages.


OncoMed Pharmaceuticals (OncoMed Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
800 Chesapeake Drive, Redwood City, CA, USA, 94063
OncoMed Pharmaceuticals Inc is a clinical-stage biotechnology company. The aim of the company is to address cancer initiation, growth, metastases, and recurrence by developing alternative therapies to fight cancer. Its core therapy uses monoclonal antibodies targeting cancer stem cells. The company has strategic alliances with Celgene, Bayer Pharma, and GlaxoSmithKline.
Executives
Perry A Karsen director C/O CELGENE CORPORATION, 86 MORRIS AVENUE, SUMMIT NJ 07901
Deepika Pakianathan director 160 BOVET ROAD, SUITE 408, C/O DELPHI VENTURES, SAN MATEO CA 94402
Jack W Lasersohn director 18 BANK STREET, SUMMIT NJ 07901
Jonathan D Root director 2735 SAND HILL ROAD, MENLO PARK CA 94025
Michael S Wyzga director RADIUS HEALTH, INC., 201 BROADWAY, 6TH FLOOR, CAMBRIDGE MA 02139
Rick E Winningham director 901 GATEWAY BOULEVARD, SOUTH SAN FRANCISCO CA 94080
Denise Scots-knight director C/O IDENIX PHARMACEUTICALS, INC., 60 HAMPSHIRE STREET, CAMBRIDGE MA 02139
Sunil Patel officer: See Remarks 11085 NORTH TORREY PINES RD., SUITE 300, LA JOLLA CA 92037
Paul J Hastings officer: Chairman & CEO 61 HARTFORD STREET, SAN FRANCISCO CA 94114
Laurence Lasky director C/O COLUMN GROUP LP, 1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158
Jakob Dupont officer: SVP & Chief Medical Officer C/O ONCOMED PHARMACEUTICALS, INC., 800 CHESAPEAKE DRIVE, REDWOOD CITY CA 94063
Terry P Gould director C/O ONCOMED PHARMACEUTICALS, INC., 800 CHESAPEAKE DRIVE, REDWOOD CITY CA 94063
Usvp Entrepreneur Partners Viii A L P 10 percent owner P O BOX 7460, MENLO PARK CA 94026
Usvp Entrepreneur Partners Viii B L P 10 percent owner P O BOX 7460, MENLO PARK CA 94026
Usvp Viii Affiliates Fund L P 10 percent owner 2735 SAND HILL ROAD, MENLO PARK CA 94025

OncoMed Pharmaceuticals (OncoMed Pharmaceuticals) Headlines

From GuruFocus

OncoMed to Present at the Cantor Global Healthcare Conference

By Marketwired Marketwired 09-24-2018

Tumor Drug Takes The Focus At OncoMed Pharmaceuticals

By reports.droy reports.droy 01-29-2015

OncoMed Announces Early Clinical Data for anti-TIGIT Antibody

By Marketwired Marketwired 11-09-2018